MedPath

Clinical Trial News

Cartesian Therapeutics' Descartes-08 Shows Promise in Myasthenia Gravis Phase 2b Trial

  • Cartesian Therapeutics' Descartes-08 met the primary endpoint in a Phase 2b trial for myasthenia gravis, demonstrating statistically significant improvement in MGC scores.
  • 71% of patients treated with Descartes-08 had clinically meaningful improvement in MGC score at Month 3, compared to 25% for placebo, highlighting its potential as a novel therapy.
  • The mRNA CAR-T therapy showed a favorable safety profile, supporting outpatient administration without the need for lymphodepleting chemotherapy, a significant advantage over traditional CAR-T therapies.
  • Updated Phase 2a results showed durable responses up to one year after retreatment, reinforcing Descartes-08's potential for long-term management of myasthenia gravis.

One-Year Trastuzumab Improves Disease-Free Survival in ERBB2-Positive Breast Cancer

  • A secondary analysis of the SOLD trial indicates that one year of adjuvant trastuzumab improves disease-free survival (DFS) compared to a 9-week regimen in patients with ERBB2-positive breast cancer.
  • The 5-year DFS rate was 90.7% in the 1-year trastuzumab group versus 87.7% in the 9-week group, highlighting a statistically significant benefit for the longer treatment duration.
  • The study suggests the 9-week regimen may be an option for patients who cannot tolerate or afford the one-year treatment, though overall survival rates were similar between both groups.
  • Longer follow-up revealed that factors such as positive axillary nodes, age, and disease stage were independently associated with the risk of death, but not the treatment duration.

The Synergism Or Long Duration (SOLD) Study

NCT00593697CompletedPhase 3
Finnish Breast Cancer Group
Posted 1/1/2008

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

NCT00629278Unknown StatusPhase 3
Azienda Ospedaliero-Universitaria di Modena
Posted 12/1/2007

Vutrisiran Shows Promise in Reducing Hospitalization and Deaths in ATTR Cardiac Amyloidosis

• A new study reveals that vutrisiran, a gene-silencing drug, significantly reduces the risk of death and cardiovascular events in patients with transthyretin (ATTR) cardiac amyloidosis. • The HELIOS-B clinical trial demonstrated a 28% reduction in the risk of death and recurring cardiovascular events over three and a half years with vutrisiran treatment. • Vutrisiran, which blocks the production of the disease-causing TTR protein, improved the quality of life and showed benefits in disease progression markers among treated patients. • The findings suggest vutrisiran could become a new standard of care for ATTR cardiac amyloidosis, offering a significant advancement in treating this progressive and often fatal disease.

Daratumumab-Based Regimens Deepen Responses and Improve MRD Negativity in Multiple Myeloma

  • Daratumumab plus lenalidomide maintenance significantly increased MRD-negative conversion rates compared to lenalidomide alone in transplant-eligible newly diagnosed multiple myeloma patients.
  • The addition of daratumumab to VRd improved MRD negativity rates in transplant-ineligible or deferred newly diagnosed multiple myeloma patients.
  • D-VRd followed by D-R maintenance resulted in higher rates of overall MRD-negativity in revised high-risk multiple myeloma subgroups.

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

NCT02874742CompletedPhase 2
Janssen Research & Development, LLC
Posted 8/29/2016

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

NCT04071457RecruitingPhase 3
SWOG Cancer Research Network
Posted 8/13/2019

MInimal Residual Disease Adapted Strategy

NCT04934475Active, Not RecruitingPhase 3
Intergroupe Francophone du Myelome
Posted 12/8/2021

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

NCT03901963Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 4/26/2019

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

NCT03652064Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 11/6/2018

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

NCT03710603Active, Not RecruitingPhase 3
Stichting European Myeloma Network
Posted 12/14/2018

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

NCT02541383CompletedPhase 3
Intergroupe Francophone du Myelome
Posted 9/1/2015

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

NCT02252172CompletedPhase 3
Janssen Research & Development, LLC
Posted 2/16/2015

IO/TKI Doublets Emerge as Standard of Care in Non-Clear Cell Renal Cell Carcinoma

• Phase 2 trials show that IO/TKI combinations, like lenvatinib plus pembrolizumab, demonstrate efficacy in non-clear cell renal cell carcinoma (non-ccRCC) with manageable safety profiles. • KEYNOTE-B61 trial reported a 51% objective response rate (ORR) in non-ccRCC patients treated with lenvatinib and pembrolizumab, supporting NCCN guideline recommendations. • Cabozantinib plus nivolumab also shows promise, with a 48% ORR in a phase 2 trial, establishing IO/TKI doublets as effective first-line options for non-ccRCC. • Treatment decisions should consider patient preference and individual data interpretation, according to Dr. Moshe Ornstein from Cleveland Clinic.

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

NCT03635892Active, Not RecruitingPhase 2
Memorial Sloan Kettering Cancer Center
Posted 8/13/2018

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

NCT02231749CompletedPhase 3
Bristol-Myers Squibb
Posted 10/16/2014

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

NCT04704219Active, Not RecruitingPhase 2
Merck Sharp & Dohme LLC
Posted 2/23/2021

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

NCT02761057CompletedPhase 2
National Cancer Institute (NCI)
Posted 7/25/2016

Access and Cost Complicate Obesity Medication Prescriptions

• Access to obesity medications is hindered by cost and insurance coverage, creating disparities in treatment. • Many insurance providers now require a diabetes diagnosis for GLP-1 receptor agonist prescriptions, limiting access for some patients. • Comprehensive obesity management includes lifestyle changes, medication, and bariatric surgery as adjuncts. • Continued use of obesity medications is often necessary for long-term weight management due to the body's natural resistance to weight loss.

Vor Biopharma Announces Positive Data and New CD45 ADC Program, Analysts See Significant Upside

• Vor Biopharma reported updated Phase 1/2 VBP101 study results showing promising relapse-free survival data in AML/MDS patients, exceeding historical benchmarks. • Initial PK data for VCAR33ALLO demonstrated in vivo expansion at the lowest dose, with dose escalation planned, indicating potential efficacy. • The company is developing a new CD45 ADC program (VADC45) for conditioning regimens, offering a fast path to commercial development and partnership opportunities. • Analysts maintain an Outperform rating with a price target of US$11.00, citing significant upside potential from trem-cel and CD45-based depletion approaches.

Denileukin Diftitox Added to NCCN Guidelines for Cutaneous T-Cell Lymphoma

  • Denileukin diftitox-cxdl (Lymphir) has been included in the NCCN Clinical Practice Guidelines in Oncology as a category 2A recommendation for CTCL treatment.
  • The inclusion is based on data from the pivotal phase 3 Study 302, which demonstrated an objective response rate of 36.2% in patients treated with denileukin diftitox.
  • Denileukin diftitox targets the IL-2 receptor and is the only CTCL therapy with this mechanism, offering a novel approach to managing the disease.
  • The NCCN's recognition may broaden access to denileukin diftitox, particularly for patients eligible for Medicare and Medicaid coverage.

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

NCT01871727CompletedPhase 3
Eisai Inc.
Posted 5/30/2013

Medtronic's Inceptiv Spinal Cord Stimulator Receives FDA Approval for Chronic Pain Relief

  • Medtronic's Inceptiv, a spinal cord stimulator, has gained FDA approval for managing chronic pain by automatically adjusting stimulation based on biological signals.
  • The device is implanted and works by sensing signals and blocking pain signals before they reach the brain, offering a potential alternative to traditional pain management.
  • Dr. Mellisa Murphy and patient Jan Hamilton highlight the device's potential to improve the quality of life for individuals struggling with persistent pain.
  • Inceptiv represents a significant advancement in neuromodulation therapy, providing personalized and responsive pain relief for chronic pain sufferers.

Text Messaging Shows Promise for Lung Cancer Screening Eligibility Assessment, But Equity Gaps Persist

  • A new study reveals 90% of respondents use text messaging regularly, with 83% willing to report smoking status via text for lung cancer screening eligibility assessment.
  • Middle-aged, college-educated, and higher-income individuals showed greater willingness to participate in text-based screening, highlighting potential disparities in reach.
  • Researchers recommend a multimodal approach to ensure equitable identification of lung cancer screening candidates across all sociodemographic groups.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.